The information received from the European Medicines Agency within the context of joint clinical assessment and joint scientific consultation shall be used exclusively for the purposes of planning and conducting the joint clinical assessments and joint scientific consultations referred to in Articles 7-21 of Regulation (EU) 2021/2282.
The European Medicines Agency shall clearly indicate the level of protection that it attributes to the information shared with the HTA secretariat within the context of joint clinical assessment and joint scientific consultation. Before providing the information received from the European Medicines Agency to the Coordination Group and to its relevant subgroups, the HTA secretariat shall attribute to this information at least an equivalent level of protection.
The members of the Coordination Group or its subgroups shall implement necessary and appropriate technical and organisational measures to ensure and protect within their organisation the confidentiality of the information received from the European Medicines Agency within the context of joint clinical assessment and joint scientific consultation. In particular, the members of the Coordination Group or its subgroups shall ensure that only their representatives appointed to the Coordination Group or its subgroups and other individuals bound by the professional secrecy obligations who have a ‘need-to-know’ may access this information.
The members of the Coordination Group or its subgroups shall immediately report to the HTA secretariat any breach or suspected breach of protection of the information received from the European Medicines Agency within the context of joint clinical assessment and joint scientific consultation.